4 results
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI207127 in combination with 120 mg QD Faldaprevir and RBV for 16 and 24 weeks in target chronically infected HCV GT1b treatment naïve patients, including a…
1. To determine the safety and tolerability of TMC649128/TMC619688 during multiple dosing in treatmentnaïve and treatment-experienced genotype 1 HCV-infected subjects at different dose regimens as 10-days and 14-days monotherapy.2. To determine the…
To test the safety and feasibility of a closed loop controller of the FiO2 based on the measured SpO2 in a NICU setting.
The project*s overarching aim is to diminish respiratory disease burden in moderate-late preterm born infants in their first year of life.We have formulated the following specific aims: 1. Determine whether bacterial lysates reduce the number and/or…